Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer
Ramona Erber(Friedrich-Alexander-Universität Erlangen-Nürnberg), Wolfgang M. Brueckl(Paracelsus Medizinische Privatuniversität), Florian Fuchs(Friedrich-Alexander-Universität Erlangen-Nürnberg), Arndt Hartmann(Universitätsklinikum Erlangen), Elke Veltrup(Siemens Healthcare (Germany)), Ralph M. Wirtz(Siemens Healthcare (Germany)), Joachim H. Ficker(Paracelsus Medizinische Privatuniversität), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Stefanie Herlein(Friedrich-Alexander-Universität Erlangen-Nürnberg), Ralf J. Rieker(Friedrich-Alexander-Universität Erlangen-Nürnberg), Claudia Giedl(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 26
Related Papers
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|660
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
|The Lancet Respiratory Medicine|2021|523
Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis
|The American Journal of Surgical Pathology|2005|411
Dose-Response Association of CD8<sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
|JAMA Oncology|2017|409
The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS
|Deutsches Ärzteblatt international|2020|258